Aspen agreement with ANI Pharmaceuticals ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) (“Aspen Holdings”) Registration number: 1985/0002935/06 Share code: APN ISIN: ZAE000066692 and its subsidiaries (collectively “Aspen” or “the Group”) ASPEN CONCLUDES AGREEMENT WITH ANI PHARMACEUTICALS IN RESPECT OF THE DISTRIBUTION OF HYDROXYPROGESTERONE CAPROATE INJECTION IN THE UNITED STATES Shareholders are referred to the voluntary announcements released on the Stock Exchange News Service (“SENS”) on 1 December 2015 and 19 February 2016 wherein it was stated that: - Aspen Global Incorporated (“AGI”), a wholly owned subsidiary of Aspen Holdings, had acquired the intellectual property and the approved Abbreviated New Drug Application in the United States in respect of the finished dose form of Hydroxyprogesterone Caproate (“HPC”) indicated for the treatment of certain female cancers and hormonal imbalances; and - AGI was in advanced negotiations with a United States pharmaceutical company with proven capabilities in this category to distribute the HPC finished dose form in the United States. Aspen takes pleasure in announcing that AGI has concluded an exclusive distribution and supply agreement with ANI Pharmaceuticals, Inc. (“ANI”) in terms whereof AGI will be responsible for supplying the HPC finished dose form, while ANI will be responsible for its marketing and distribution in the US. Aspen currently manufactures the active pharmaceutical ingredient (“API”) for HPC and is a substantial supplier of HPC API to the United States. Aspen's launch of HPC injection is a realisation of Aspen’s stated intent to develop commercial opportunities in the United States which are aligned to the intellectual property available within the Group and the conclusion of this agreement signals a further milestone in the achievement of this stated intent. Durban 17 May 2016 Sponsor: Investec Bank Limited Date: 17/05/2016 11:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.